207
IRUS TotalDownloads
Altmetric
Circulating microRNAs in small-bowel neuroendocrine tumors: a potential tool for diagnosis and assessment of effectiveness of surgical resection
File | Description | Size | Format | |
---|---|---|---|---|
Accepted Manuscript_Serum miRNAs in SBNET_PAPER_R1 (1).docx | Accepted version | 179.12 kB | Microsoft Word | View/Open |
Title: | Circulating microRNAs in small-bowel neuroendocrine tumors: a potential tool for diagnosis and assessment of effectiveness of surgical resection |
Authors: | Malczewska, A Frampton, AE Mato Prado, M Ameri, S Dabrowska, AF Zagorac, S Clift, AK Kos-Kudła, B Faiz, O Stebbing, J Castellano, L Frilling, A |
Item Type: | Journal Article |
Abstract: | OBJECTIVE: To discover serum-based microRNA (miRNA) biomarkers for small-bowel neuroendocrine tumors (SBNET) to help guide clinical decisions. BACKGROUND: MiRNAs are small noncoding RNA molecules implicated in the initiation and progression of many cancers. MiRNAs are remarkably stable in bodily fluids, and can potentially be translated into clinically useful biomarkers. Novel biomarkers are needed in SBNET to determine disease aggressiveness, select patients for treatment, detect early recurrence, and monitor response. METHODS: This study was performed in 3 stages (discovery, validation, and a prospective, longitudinal assessment). Discovery comprised of global profiling of 376 miRNA in sera from SBNET patients (n = 11) versus healthy controls (HCs; n = 3). Up-regulated miRNAs were subsequently validated in additional SBNET (n = 33) and HC sera (n = 14); and then longitudinally after SBNET resection (n = 12), with serial serum sampling (preoperatively day 0; postoperatively at 1 week, 1 month, and 12 months). RESULTS: Four serum miRNAs (miR-125b-5p, -362-5p, -425-5p and -500a-5p) were significantly up-regulated in SBNET (P < 0.05; fold-change >2) based on multiple normalization strategies, and were validated by RT-qPCR. This combination was able to differentiate SBNET from HC with an area under the curve of 0.951. Longitudinal assessment revealed that miR-125b-5p returned towards HC levels at 1 month postoperatively in patients without disease, whereas remaining up-regulated in those with residual disease (RSD). This was also true at 12 months postoperatively. In addition, miR-362-5p appeared up-regulated at 12 months in RSD and recurrent disease (RCD). CONCLUSIONS: Our study represents the largest global profiling of serum miRNAs in SBNET patients, and the first to evaluate ongoing serum miRNA expression changes after surgical resection. Serum miR-125b-5p and miR-362-5p have potential to be used to detect RSD/RCD. |
Issue Date: | 1-Jul-2021 |
Date of Acceptance: | 1-Aug-2019 |
URI: | http://hdl.handle.net/10044/1/72516 |
DOI: | 10.1097/SLA.0000000000003502 |
ISSN: | 0003-4932 |
Publisher: | Lippincott, Williams & Wilkins |
Start Page: | e1 |
End Page: | e9 |
Journal / Book Title: | Annals of Surgery |
Volume: | 274 |
Issue: | 1 |
Copyright Statement: | © 2019 Wolters Kluwer Health, Inc. All rights reserved. This document is the Accepted Manuscript version of a published work that appeared in final form in Annals of Surgery, 1 August 2019, https://doi.org/10.1097/SLA.0000000000003502 |
Sponsor/Funder: | Dr. Heinz-Horst Deichmann Stiftung Cancer Research UK National Institute for Health Research Imperial College Healthcare NHS Trust- BRC Funding |
Funder's Grant Number: | n/a 22664 NIHR-RP-011-053 RDB01 79560 |
Keywords: | Surgery 11 Medical and Health Sciences |
Publication Status: | Published |
Conference Place: | United States |
Online Publication Date: | 2019-08-01 |
Appears in Collections: | Department of Surgery and Cancer Faculty of Medicine |